Supplementation of glutamine and omega-3 polyunsaturated fatty acids as a novel therapeutic intervention targeting metabolic dysfunction and exercise intolerance in patients with heart failure

Current Clinical Pharmacology

Volumn 6, Issue 4, 2011, Pages 288-294

  Shahzad, Khurram ^a   Chokshi, Aalap ^a   Schulze, Christian P ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Exercise tolerance; Fish oil; Glutamine; Heart failure; Metabolism; Omega 3 polyunsaturated fatty acids

Indexed keywords

GLUTAMINE; MALTODEXTRIN; OMEGA 3 FATTY ACID;

AEROBIC METABOLISM; ANTIARRHYTHMIC ACTIVITY; CACHEXIA; DIET SUPPLEMENTATION; DRUG EFFECT; FATTY ACID METABOLISM; FUNCTIONAL STATUS; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; INFLAMMATION; LIPOLYSIS; METABOLIC DISORDER; MUSCLE FUNCTION; MUSCLE METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SKELETAL MUSCLE METABOLISM;

EID: 83455224455     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488411798375958     Document Type: Review

References (64)

1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348(20): 2007-18.
2. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 2007; 356(11): 1140-51.
3. Duscha BD, Schulze PC, Robbins JL, Forman DE. Implications of chronic heart failure on peripheral vasculature and skeletal muscle before and after exercise training. Heart Fail Rev 2008; 13(1): 21-37.
4. Stanley WC, Recchia FA, Lopaschuk G. Myocardial substrate metabolism in the normal and failing heart. Physiology Rev 2005; 85(3): 1093-129.
5. Hue L, Taegtmeyer H. The Randle cycle revisited: a new head for an old hat. Am J Physiol Endocrinol Metab 2009; 297(3): E578-591.
6. Rajabi M, Kassiotis C, Razeghi P, Taegtmeyer H. Return to the fetal gene program protects the stressed heart: a strong hypothesis. Heart Fail Rev 2007; 12(3-4): 331-343.
7. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart. Circulation 2001; 104(24): 2923-2931.
8. Karbowska J, Kochan Z, Smoleński RT. Peroxisome proliferatoractivated receptor alpha is downregulated in the failing human heart. Cell Mol Biol 2003; 8(1): 49-53.
9. Di Lisa F, Fan CZ, Gambassi G, Hogue BA, Kudryashova I, Hansford RG. Altered pyruvate dehydrogenase control and mitochondrial free Ca2+ in hearts of cardiomyopathic hamsters. Am J Physiol 1993; 264(6 Pt 2): H2188-2197.
10. Bersin RM, Stacpoole PW.Dichloroacetate as metabolic therapy for myocardial ischemia and failure. Am Heart J 1997; 134(5 Pt 1): 841-855.
11. Drexler H, Riede U, Münzel T, König H, Funke E, Just H. Alterations of skeletal muscle in chronic heart failure. Circulation 1992; 85(5): 1751-1759.
12. Simonini A, Long CS, Dudley GA, Yue P, McElhinny J, Massie BM. Heart failure in rats causes changes in skeletal muscle morphology and gene expression that are not explained by reduced activity. Circ Res 1996; 79(1): 128-136.
13. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7(1): 11-20.
14. Bowtell JL, Marwood S, Bruce M, Constantin-Teodosiu D, Greenhaff PL. Tricarboxylic acid cycle intermediate pool size: functional importance for oxidative metabolism in exercising human skeletal muscle. Sports Med 2007; 37(12): 1071-1088.
15. Sahlin K, Katz A, Broberg S. Tricarboxylic acid cycle intermediates in human muscle during prolonged exercise. Am J Physiol 1990; 259(5 Pt 1): C834-841.
16. Russell RR 3rd, Taegtmeyer H. Pyruvate carboxylation prevents the decline in contractile function of rat hearts oxidizing acetoacetate. Am J Physiol 1991; 261(6 Pt 2): H1756-62.
17. Gibala MJ, Young ME, Taegtmeyer H. Anaplerosis of the citric acid cycle: role in energy metabolism of heart and skeletal muscle. Acta Physiol Scand 2000; 168(4): 657-65.
18. Cooney GJ, Taegtmeyer H, Newsholme EA. Tricarboxylic acid cycle flux and enzyme activities in the isolated working rat heart. Biochem J 1981; 200(3): 701-3.
19. Rennie MJ, Bowtell JL, Bruce M, Khogali SE. Interaction between glutamine availability and metabolism of glycogen, tricarboxylic acid cycle intermediates and glutathione. J Nutr 2001; 131(9 Suppl): 2496-2497.
20. Constantin-Teodosiu D, Simpson EJ, Greenhaff PL. The importance of pyruvate availability to PDC activation and anaplerosis in human skeletal muscle. Am J Physiol 1999; 276(3 Pt 1): E472-478.
21. Russell RR 3rd, Taegtmeyer H. Changes in citric acid cycle flux and anaplerosis antedate the functional decline in isolated rat hearts utilizing acetoacetate. J Clin Invest 1991; 87(2): 384-390.
22. Hermann HP, Pieske B, Schwarzmüller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 1999; 353(9161): 1321-3.
23. Bittner V. Determining prognosis in congestive heart failure: role of the 6-minute walk test. Am Heart J 1999; 138(4 Pt 1): 593-596.
24. Felker GM, Whellan D, Kraus WE, et al. N-terminal pro-brain natriuretic peptide and exercise capacity in chronic heart failure: data from the Heart Failure and a Controlled Trial Investigating Outcomes of Exercise Training (HF-ACTION) study. Am Heart J 2009; 158(4 Suppl): S37-44.
25. Gardin JM, Leifer ES, Fleg JL, et al. Relationship of Doppler- Echocardiographic left ventricular diastolic function to exercise performance in systolic heart failure: the HF-ACTION study. Am Heart J 2009; 158(4 Suppl): S45-52.
26. Russell SD, Saval MA, Robbins JL, et al. New York Heart Association functional class predicts exercise parameters in the current era. Am Heart J 2009; 158(4 Suppl): S24-30.
27. Hambrecht R, Schulze PC, Gielen S, et al. Effects of exercise training on insulin-like growth factor-I expression in the skeletal muscle of non-cachectic patients with chronic heart failure. Eur J Cardiovasc Prev Rehabil 2005; 12(4): 401-406.
28. Piña IL, Apstein CS, Balady GJ, et al. Exercise and heart failure: A statement from the American Heart Association Committee on exercise, rehabilitation, and prevention. Circulation 2003; 107(8): 1210-1225.
29. Hülsmann M, Quittan M, Berger R, et al. Muscle strength as a predictor of long-term survival in severe congestive heart failure. Eur J Heart Fail 2004; 6(1): 101-7.
30. Clark A, Rafferty D, Arbuthnott K. Relationship between isokinetic muscle strength and exercise capacity in chronic heart failure. Int J Cardiol 1997; 59(2): 145-148.
31. Degache F, Garet M, Calmels P, Costes F, Bathélémy JC, Roche F. Enhancement of isokinetic muscle strength with a combined training programme in chronic heart failure. Clin Physiol Funct Imaging 2007; 27(4): 225-230.
32. van Norren K, Kegler D, Argilés JM, et al. Dietary supplementation with a specific combination of high protein, leucine, and fish oil improves muscle function and daily activity in tumour-bearing cachectic mice. Br J Cancer 2009; 100(5): 713-722.
33. Persinger R, Janssen-Heininger Y, Wing SS, Matthews DE, LeWinter MM, Toth MJ. Effect of heart failure on the regulation of skeletal muscle protein synthesis, breakdown, and apoptosis. Am J Physiol Endocrinol Metab 2003; 284(5): E1001-1008.
34. Schulze PC, Fang J, Kassik KA, et al. Transgenic overexpression of locally acting insulin-like growth factor-1 inhibits ubiquitinmediated muscle atrophy in chronic left-ventricular dysfunction. Circ Res 2005; 97(5): 418-426.
35. VanderHeiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324(5930): 1029-1033.
36. Bowtell JL, Gelly K, Jackman ML, Patel A, Simeoni M, Rennie MJ. Effect of oral glutamine on whole body carbohydrate storage during recovery from exhaustive exercise. J Appl Physiol 1999; 86(6): 1770-77.
37. Ohtani M, Sugita M, Maruyama K. Amino acid mixture improves training efficiency in athletes. J Nutr 2006; 136(2): 538S-543S.
38. Rutten EP, Engelen MP, Schols AM, Deutz NE. Skeletal muscle glutamate metabolism in health and disease: state of the art. Curr Opin Clin Nutr Metab Care 2005; 8(1): 41-51.
39. Gleeson M. Dosing and efficacy of glutamine supplementation in human exercise and sport training. J Nutr 2008; 138(10): 2045S-2049S.
40. DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104(49): 19345-19350.
41. Berger MM, Mustafa I. Metabolic and nutritional support in acute cardiac failure. Curr Opin Clin Nutr Mtab Care 2003; 6(2): 195-201.
42. Khogali SE, Pringle SD, Weryk BV, Rennie MJ. Is glutamine beneficial in ischemic heart disease? Nutrition 2002; 18(2): 123-126.
43. Bowtell JL, Bruce M. Glutamine: an anaplerotic precursor. Nutrition 2002; 18(3): 222-224.
44. Scognamiglio R, Avogaro A, Negut C, Piccolotto R, de Kreutzenberg SV, Tiengo A. The effects of oral amino acid intake on ambulatory capacity in elderly subjects. Aging Clin Exp Res 2004; 16(6): 443-447.
45. Aquilani R, Viglio S, Iadarola P, et al. Oral amino acid supplements improve exercise capacities in elderly patients with chronic heart failure. Am J Cardiol 2008; 101(11A): 104E-110E.
46. Scognamiglio R, Negut C, Piccolotto R, Dioguardi FS, Tiengo A, Avogaro A. Effects of oral amino acid supplementation on myocardial function in patients with type 2 diabetes mellitus. Am Heart J 2004; 147(6): 1106-1112.
47. Eaton S. Impaired energy metabolism during neonatal sepsis: the effects of glutamine. Proc NutrSoc 2003; 62(3): 745-751.
48. Engel JM, Pitz S, Mühling J, et al. Role of glutamine administration on T-cell derived inflammatory response after cardiopulmonary bypass. Clin Nutr 2009; 28(1): 15-20.
49. Langenberg CJ, Pietersen HG, Geskes G, et al. The effect of glutamate infusion on cardiac performance is independent of changes in metabolism in patients undergoing routine coronary artery bypass surgery. Clin Sci 2001; 101(6): 573-580.
50. Favano A, Santos-Silva PR, Nakano EY, Pedrinelli A, Hernandez AJ, Greve JM. Peptide glutamine supplementation for tolerance of intermittent exercise in soccer players. Clinics (Sao Paulo) 2008; 63(1): 27-32.
51. Duda MK, O'Shea KM, Stanley WC. Omega-3 polyunsaturated fatty acid supplementation for the treatment of heart failure: mechanisms and clinical potential. Cardiovasc Res 2009; 84(1): 33-41.
52. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol 2009; 54(7): 585-594.
53. Gissi-HF Investigators, Tavazzi L, Maggioni AP, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebocontrolled trial. Lancet 2008; 372(9645): 1223-1230.
54. Finzi AA, Latini R, Barlera S, et al. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the GruppoItaliano per lo Studio dellaSopravvivenzanell'InsufficienzaCardiaca (GISSI-HF) trial. Am Heart J 2011; 161(2): 338-343.
55. Levitan EB, Wolk A, Mittleman MA. Fatty fish, marine omega-3 fatty acids and incidence of heart failure. Eur J Clin Nutr 2010; 64(6): 587-94.
56. Nodari S, Triggiani M, Campia U, et al. Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy. J Am Coll Cardiol 2011; 57(7): 870-9.
57. Burr ML, Fehily AM, Gilbert JF, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2(8666): 757-761.
58. Oikawa S, Yokoyama M, Origasa H, et al. Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 2009; 206(2): 535-539.
59. Mozaffarian D, Lemaitre RN, King IB, et al. Circulating Long- Chain {omega}-3 Fatty Acids and Incidence of Congestive Heart Failure in Older Adults: The Cardiovascular Health Study: A Cohort Study. Ann Intern Med 2011; 155(3): 160-70.
60. Moertl D, Hammer A, Steiner S, Hutuleac R, Vonbank K, Berger R. Dose-dependent effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of nonischemic origin: a double-blind, placebo-controlled, 3-arm study. Am Heart J 2011; 161(5): 915.e1-9.
61. Peoples GE, McLennan PL, Howe PR, Groeller H. Fish oil reduces heart rate and oxygen consumption during exercise. J Cardiovasc Pharmacol 2008; 52(6): 540-547.
62. Bortolotti M, Tappy L, Schneiter P. Fish oil supplementation does not alter energy efficiency in healthy males. Clin Nutr 2007; 26(2): 225-230.
63. Brown TT, Zelnik DL, Dobs AS. Fish oil supplementation in the treatment of cachexia in pancreatic cancer patients. Int J Gastrointest Cancer 2003; 34(2-3): 143-150.
64. Barber MD, Fearon KC, Tisdale MJ, McMillan DC, Ross JA. Effect of a fish oil-enriched nutritional supplement on metabolic mediators in patients with pancreatic cancer cachexia. Nutr Cancer 2001; 40(2): 118-124.